Cargando…

The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia

Background: The aim of this study was to investigate the impact of selected legislative initiatives and their implementation for off-patent medicinal products in Slovakia compared with the rest of the Visegrád Group (V4 countries). Methods: We analyzed the development of applications for the reimbur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tesar, Tomas, Golias, Peter, Masarykova, Lucia, Kawalec, Paweł, Inotai, András
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710743/ https://www.ncbi.nlm.nih.gov/pubmed/34966285 http://dx.doi.org/10.3389/fphar.2021.795002

Ejemplares similares

Potential Cost-Savings From the Use of the Biosimilars in Slovakia
por: Tesar, Tomas, et al.
Publicado: (2020)

How Changes in Reimbursement Practices Influence the Financial Sustainability of Medicine Policy: Lessons Learned from Slovakia
por: Tesar, Tomas, et al.
Publicado: (2019)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Consumption of Antibacterials for Systemic Use in Slovakia: A National Study and the Quality Indicators for Outpatient Antibiotic Use
por: Tesar, Tomas, et al.
Publicado: (2021)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2019)

Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2018)

Analysis of spontaneous reports of suspected adverse reactions after vaccination against COVID-19 in Slovakia
por: Lassanova, Monika, et al.
Publicado: (2023)

Dynamics of price competition in Italian pharmaceutical off-patent market
por: Perna, Serena, et al.
Publicado: (2022)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
por: Stawowczyk, Ewa, et al.
Publicado: (2019)

Evaluating the benefits of TNF-alfa inhibitor biosimilar competition on off-patent and on-patent drug markets: A Southern European analysis
por: Barcina Lacosta, Teresa, et al.
Publicado: (2022)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer
por: Tesar, Tomas, et al.
Publicado: (2017)

How Can We Optimize the Value Assessment and Appraisal of Orphan Drugs for Reimbursement Purposes? A Qualitative Interview Study Across European Countries
por: Blonda, Alessandra, et al.
Publicado: (2022)

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives
por: Kaló, Zoltán, et al.
Publicado: (2021)

Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
por: Inotai, Andras, et al.
Publicado: (2018)

Assessing the Accuracy of Sales Forecasts Submitted by Pharmaceutical Companies Applying for Reimbursement in Austria
por: Kossmeier, Michael, et al.
Publicado: (2021)

Availability and Accessibility of Orphan Medicinal Products to Patients in Slovakia in the Years 2010–2019
por: Foltanova, Tatiana, et al.
Publicado: (2022)

Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
por: Badora, Karolina, et al.
Publicado: (2017)

Recent Advances in Pharmaceutical Cocrystals: From Bench to Market
por: Kumar Bandaru, Ravi, et al.
Publicado: (2021)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions
por: Simeonidis, Stavros, et al.
Publicado: (2019)

Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe
por: Malinowski, Krzysztof Piotr, et al.
Publicado: (2020)

Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
por: Kamusheva, Maria, et al.
Publicado: (2018)

Critical Appraisal of Reimbursement List in Bosnia and Herzegovina
por: Mujkic, Sabina, et al.
Publicado: (2017)

Critical Reflections on Reimbursement and Access of Advanced Therapies
por: Simoens, Steven, et al.
Publicado: (2022)

Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings
por: Petykó, Zsuzsanna Ida, et al.
Publicado: (2021)

Genetics and genomic medicine in Slovakia
por: Kádaši, Ludevít, et al.
Publicado: (2015)

A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges
por: Vella Bonanno, Patricia, et al.
Publicado: (2021)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Evolution of Ethical Principles in the Practice of Pharmaceutical Medicine From a UK Perspective
por: Morris, Thomas, et al.
Publicado: (2020)

Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans
por: Salek, Sam, et al.
Publicado: (2019)

Editorial: Grand Challenges in Pharmaceutical Medicine: Competencies and Ethics in Medicines Development
por: Silva, Honorio, et al.
Publicado: (2021)

Chinese Patent Medicines in the Treatment of Coronavirus Disease 2019 (COVID-19) in China
por: Zhuang, Wei, et al.
Publicado: (2020)

Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review
por: Yang, Zhi-Hua, et al.
Publicado: (2021)

Reimbursement decision-making system in Poland systematically compared to other countries
por: Mela, Aneta, et al.
Publicado: (2023)

Impact of Biologic Treatment of Crohn’s Disease on the Rate of Surgeries and Other Healthcare Resources: An Analysis of a Nationwide Database From Poland
por: Holko, Przemysław, et al.
Publicado: (2018)

Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges
por: Kardas, Przemysław, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jbk15r7bumbbrsqsfrpvp2uint